Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Profusa ( (PFSA) ) just unveiled an update.
On May 13, 2026, Profusa received confirmation from Nasdaq that it had met the May 11 deadline to apply to transfer its listing, and its shares were scheduled to move from their prior tier to The Nasdaq Capital Market effective at the market open on May 15, 2026. The transfer, announced in a May 15 press release, is the first in a series of interim milestones set by a Nasdaq Hearings Panel as Profusa works to regain and maintain compliance with bid-price and stockholders’ equity listing rules, leaving investors exposed to ongoing uncertainty over the company’s ability to keep its stock listed.
The Panel previously granted Profusa an exception to continue trading while it executes a compliance plan tied to Nasdaq’s Bid Price Rule and Equity Rule, in lieu of meeting the market value of listed securities alternative. The company is evaluating the conditions imposed and intends to take required actions within specified time frames, but it has cautioned there is no assurance it will satisfy all listing criteria or avoid a future delisting from The Nasdaq Capital Market.
More about Profusa
Profusa, Inc. is a Berkeley, California-based commercial-stage digital health company developing tissue-integrated, long-lasting injectable biosensors and an intelligent data platform to enable continuous monitoring of an individual’s biochemistry. Its medical-grade, affordable biosensors are designed to deliver personalized biochemical data that clinicians can trust for both personal and clinical use, with products marketed under the LUMEE and Profusa brands in multiple global regions.
Average Trading Volume: 5,091,982
Technical Sentiment Signal: Sell
Current Market Cap: $1.89M
See more insights into PFSA stock on TipRanks’ Stock Analysis page.